Quantcast

Syndax Pharmaceuticals Announces Entinostat Data at 102nd Annual American Association for Cancer Research Meeting

March 31, 2011

WALTHAM, Mass., March 31, 2011 /PRNewswire/ — Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today announced 11 posters on entinostat, an oral, highly selective, class I histone deacetylase (HDAC) inhibitor, will be presented at the 102nd Annual American Association for Cancer Research meeting April 2 to April 6 in Orlando, FL.

“The breadth of exciting data being presented at AACR provides additional insight into the opportunities for Syndax to build out our entinostat development program,” said Joanna Horobin, president and chief executive officer of Syndax. “The AACR presentations add to the growing body of evidence supporting the potential for entinostat in solid tumors including the promising results with entinostat in combination with Tarceva® in advanced non-small-cell lung cancer which were presented at the end of last year. Recently we completed our randomized, placebo-controlled phase 2 clinical trial in metastatic breast cancer which will be presented at a scientific conference later this year and are aggressively moving forward with a pivotal program in this patient population.”


    The following posters will be presented Monday, April 4:
    Time:               8:00 AM to 12:00 PM EDT:
    Presentation #:                                                      1146
                         Multiple HDAC inhibitors (HDACi) reduce the
                         expression of the oncogenic miR-17~92 cluster; a
    Title:               pan HDACi class effect
    Location:           Exhibit Hall A4-C, Poster Section 7

    Time:               8:00 AM to 12:00 PM EDT:
    Presentation #:                                                      1792
                         Selective class I HDAC inhibitor SNDX-275 enhances
                         anti-tumor survivin vaccine therapy by suppressing
    Title:               regulatory T cells in a model of prostate cancer
    Location:           Exhibit Hall A4-C, Poster Section 32

    Time:               1:00 to 5:00 PM EDT:
    Presentation #:                                                      2018
                         Combination therapy with vidaza and entinostat
                         suppresses tumor growth and reprograms the
    Title:               epigenome in an orthotopic lung cancer model
    Location:           Exhibit Hall A4-C, Poster Section 3

    Time:               1:00 to 5:00 PM EDT:
    Presentation #:                                                      2572
                         The histone deacetylase inhibitors (HDACIs)
                         vorinostat and entinostat interact synergistically
                         with the Bcr/Abl, FLT3, and aurora kinase
                         inhibitor KW-2449 to induce apoptosis in imatininb
                         mesylate (IM)-sensitive and -resistant CML and
    Title:               ALL cells
    Location:           Exhibit Hall A4-C, Poster Session 27

    Time:               1:00 to 5:00 PM EDT:
    Presentation #:                                                      2614
                         Inhibition of class I histone deacetylases
                         attenuates anthracycline induced activation of the
    Title:               ATM pathway
    Location:           Exhibit Hall A4-C, Poster Session 29

    Time:               1:00 to 5:00 PM EDT:
    Presentation #:                                                      2618
                         DNMT1 as a marker of differential sensitivities to
                         epigenetic therapy of a Kras mutant and Kras wild
    Title:               type human non small cell lung cancer cell line
    Location:           Exhibit Hall A4-C, Poster Session 29

    Time:               1:00 to 5:00 PM EDT:
    Presentation #:                                                      2633
                         Histone deacetylase inhibitors induce CXCR4 mRNA but
    Title:               antagonize CXCR4 migration
    Location:           Exhibit Hall A4-C, Poster Session 29

    The following posters will be presented Tuesday, April 5:
    Time:               8:00 AM to 12:00 PM EDT:
    Presentation #:                                                      3519
                         Histone deacetylase inhibitors upregulates thymidine
                         phosphorylase gene and protein expression and
    Title:               synergize with capecitabine in breast cancer cells
    Location:           Exhibit Hall A4-C, Poster Session 26

    Time:               1:00 to 5:00 PM EDT:
    Presentation #:     LB-411
                         A phase II study of combination epigenetic therapy
    Title:               in advanced non-small cell lung cancer
    Location:           Exhibit Hall A4-C, Poster Session 40

    The following posters will be presented Wednesday, April 6:
    Time:               8:00 AM to 12:00 PM EDT:
    Presentation #:                                                      5335
                         The histone deacetylase inhibitor MS-275 sensitizes
                         osteosarcoma cells and osteosarcoma lung metastases
                         to FasL-induced cell death by the downregulation
    Title:               c-FLIP
    Location:           Exhibit Hall A4-C, Poster Session 25

    Time:               8:00 AM to 12:00 PM EDT:
    Presentation #:                                                      5048
                         Targeting regulators of Chk1 to enhance cytotoxic
    Title:               efficacy of HDAC inhibitors
    Location:           Exhibit Hall A4-C, Poster Session 12

About Entinostat

Entinostat is an orally bioavailable, highly selective, class I histone deacetylase (HDAC) inhibitor with a long half-life that allows for weekly or every-other-week dosing. Entinostat is being studied in advanced breast cancer in combination with aromatase inhibitors and recently completed a randomized, placebo-controlled phase 2 trial in this patient population. The results will be presented at a scientific conference later this year. Entinostat also is being studied in various cancers including advanced non-small-cell lung cancer and advanced colorectal cancer in combination with azacitidine. At the end of last year, results were presented from a randomized phase 2 study showing a four-month survival advantage when entinostat was added to erlotinib in patients with lung cancers expressing high levels of E-cadherin. Syndax has several studies ongoing under a cooperative research and development agreement with the National Cancer Institute.

Research has shown that HDACs are involved in the expression of various genes, such as the estrogen receptor, that regulate cell growth, differentiation and apoptosis. Such genes are frequently silenced in cancer cells through the over-expression of enzymes including HDACs. HDACs are therefore recognized as promising targets for cancer treatment. Further, studies have demonstrated that HDAC inhibition can significantly enhance anti-cancer activity when used in combination with a broad range of anti-cancer agents. The potential therefore exists to overcome tumor resistance to targeted agents.

About Syndax

Syndax Pharmaceuticals, Inc. is a Waltham, MA-based, oncology-focused pharmaceutical company. Syndax is building a portfolio of new oncology products to extend and improve the lives of patients by developing and commercializing novel cancer therapies in optimized, mechanistically driven combination regimens. Formed in 2005, the company’s intellectual property is based on work from scientific founder Ronald Evans, Ph.D., recipient of the 2004 Albert Lasker Prize for Basic Medical Research, a Member of the National Academy of Sciences, a professor at the Salk Institute for Biological Studies and a Howard Hughes Medical Institute Investigator. Syndax has worldwide rights to develop and commercialize entinostat and is backed by top-tier Venture Capital firms: Domain Associates, MPM Capital, Avalon, Pappas and Forward Ventures. For more information please visit www.syndax.com.

Contact Information
E. Blair Schoeb
Syndax Pharmaceuticals, Inc
Tel: 908-277-0386
bschoeb@syndax.com

SOURCE Syndax Pharmaceuticals, Inc.


Source: newswire



comments powered by Disqus